Holen Sie sich die Stockscreener-App
0.1515
2.38%
-0.0037
Handel nachbörslich:
.07
-0.0815
-53.80%
Schlusskurs vom Vortag:
$0.1552
Offen:
$0.1475
24-Stunden-Volumen:
1.45M
Relative Volume:
0.54
Marktkapitalisierung:
$6.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-43.29M
KGV:
-0.1377
EPS:
-1.1
Netto-Cashflow:
$-34.80M
1W Leistung:
-11.66%
1M Leistung:
-5.84%
6M Leistung:
-68.37%
1J Leistung:
-73.42%
1-Tages-Spanne:
$0.1475
$0.1587
1-Wochen-Bereich:
$0.145
$0.1799
52-Wochen-Spanne:
$0.1315
$1.31
Viracta Therapeutics Inc Stock (VIRX) Company Profile
Firmenname
Viracta Therapeutics Inc
Sektor
Branche
Telefon
858-400-8470
Adresse
2533 S COAST HWY 101, CARDIFF
Vergleichen Sie VIRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIRX
Viracta Therapeutics Inc
|
0.1515 | 6.02M | 0 | -43.29M | -34.80M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viracta Therapeutics Inc Stock (VIRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-16 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-02-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-26 | Eingeleitet | SVB Leerink | Outperform |
| 2021-03-25 | Eingeleitet | Evercore ISI | Outperform |
Viracta Therapeutics Inc Aktie (VIRX) Neueste Nachrichten
Viracta Therapeutics strikes deal to avoid default - MSN
Viracta Therapeutics strikes deal to avoid default By Investing.com - Investing.com South Africa
Viracta Therapeutics (VIRX) Stock Price, News & Analysis - MarketBeat
Viracta Therapeutics faces Nasdaq delisting over audit issue By Investing.com - Investing.com Canada
Viracta Therapeutics faces Nasdaq delisting over audit issue - MSN
BioLineRx announces $10M registered direct offering; shares tumble - MSN
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
North American Morning Briefing : Boeing Stock -2- - Marketscreener.com
Viracta Therapeutics (NASDAQ:VIRX) Given “Neutral” Rating at Rodman & Renshaw - Defense World
Rodman & Renshaw Downgrades Viracta Therapeutics (VIRX) - MSN
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure - Yahoo Finance
Deal Dispatch: Party City Wraps Up, Big Lots Goes Bust, The Container Store Continues - Benzinga
Castellum, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday (CORRECTED) - Benzinga
ServiceTitan initiated, Viracta downgraded: Wall Street's top analyst calls - Yahoo Finance
Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha
Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday - Benzinga
Constellium, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday - Benzinga
Viracta Therapeutics, Inc. Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - Marketscreener.com
Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives - MarketWatch
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - GlobeNewswire
Viracta Therapeutics (VIRX) Halts Phase 2 NAVAL-1 Trial, Explores Strategic Alternatives Amid Resource Conservation - StockTitan
Viracta Therapeutics' SWOT analysis: stock focus narrows amid pipeline shift - Investing.com
Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Update - Defense World
Viracta Therapeutics Inc (NASDAQ: VIRX) Has Great Upside Potential - Stocks Register
Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook By Investing.com - Investing.com Australia
Epstein-Barr Virus (EBV) Market A Deep Dive into Current - openPR
Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook - Investing.com
Viracta Therapeutics faces Nasdaq delisting over non-compliance By Investing.com - Investing.com Australia
Viracta Therapeutics faces Nasdaq delisting over non-compliance - Investing.com
Viracta Therapeutics faces Nasdaq delisting risk - Investing.com India
Viracta Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Canada
Volkswagen Ag ADR (VWAGY) QuotePress Release - The Globe and Mail
Contrasting ALX Oncology (NASDAQ:ALXO) & Viracta Therapeutics (NASDAQ:VIRX) - Defense World
Royal Bank of Canada Cuts Viracta Therapeutics (NASDAQ:VIRX) Price Target to $2.00 - Defense World
VIRX stock touches 52-week low at $0.15 amid market challenges - Investing.com UK
Viracta Therapeutics Highlights Strategic Focus and Financials - TipRanks
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Sunesis: Q3 Earnings Snapshot - mySA
Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Head and Neck Cancer Market Expected to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR As Revealed In N... - WhaTech
Natural Killer T-Cell Lymphoma Market 2024 Projections, - openPR
Viracta Thera pins hopes on lead lymphoma program - The Pharma Letter
Finanzdaten der Viracta Therapeutics Inc-Aktie (VIRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):